Capricor Therapeutics (NASDAQ:CAPR) Trading 6.6% Higher – Still a Buy?

Capricor Therapeutics Inc (NASDAQ:CAPR) shares shot up 6.6% on Thursday . The stock traded as high as $13.30 and last traded at $13.48. 457,699 shares changed hands during mid-day trading, a decline of 66% from the average session volume of 1,334,590 shares. The stock had previously closed at $12.65.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Tuesday. Cantor Fitzgerald upped their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Trading Up 6.8 %

The firm has a market cap of $614.07 million, a P/E ratio of -12.74 and a beta of 4.08. The company’s 50-day moving average is $14.37 and its two-hundred day moving average is $13.93.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CAPR. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Capricor Therapeutics in the 4th quarter valued at $462,000. Voloridge Investment Management LLC bought a new position in shares of Capricor Therapeutics during the fourth quarter valued at about $1,678,000. Woodline Partners LP purchased a new position in Capricor Therapeutics during the fourth quarter worth about $8,693,000. Two Sigma Investments LP grew its position in Capricor Therapeutics by 223.6% in the 4th quarter. Two Sigma Investments LP now owns 119,047 shares of the biotechnology company’s stock worth $1,643,000 after purchasing an additional 82,254 shares in the last quarter. Finally, Rafferty Asset Management LLC purchased a new stake in Capricor Therapeutics in the 4th quarter valued at about $1,743,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.